Replies to post #88975 on Avid Bioservices Inc (CDMO)

[geocappy1]

Endoc

Not a cure yet. However, in addition to what it might do for those with early diagnosis, isn't it possible that because of bavi's unique MOA we might see a whole lot more combination trials to go after a whole lot more cancers and other diseases.

[koman]

Entdoc, thanks for your response. your post made me think of a slogan, "Get a Bavi shot a year and keep Cancer at bay... and HCV,etc" On a different note, I remember someone talking a while back about getting a totally humanized version of Bavi mAb which might increase efficacy, but I wonder if it may have the opposite effect. Part of Bavi MOA may be the human immune system reacting to Bavi as a foreign antigen which may enhance efficacy ot this therapy along with other antibody therapies. There is a term coined for this observed phenomena (HAMA I think). As for all the arguments whether these pII data is statistically sig to move to PIII, HELLO- pIII purpose IS to prove whether anything seen as potential in a pII IS statistically significant. I believe Mr. Shan stated that. and IF the MOS along with other data is as great as PPHM management wants us to believe, then a pIII is a certainty with MOS as an end point or preferably percentage survival at 2 time points. And MOS is NOT a surrogate end point but the most meaningful end point. PFS and ORR are the surrogate end points that hopefully translates to a meaningful MOS increase which FDA has found out is not always the case (ie Avastin in breast cancer.